Simris Alg AB (FRA:5LU) Other Current Liabilities: €1.17 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5LU Simris Alg AB FRA:5LU
19 GF Score
Price €0.01
! 6 Warning Signs
View Full Analysis

What is Simris Alg AB Other Current Liabilities?

Simris Alg AB FRA:5LU -15.15% 19 Other Current Liabilities is €1.17 Mil as of Mar. 2026. GuruFocus rates FRA:5LU with a GF Score™ of 19/100. The stock has 6 warning signs investors should review.

Simris Alg AB's other current liabilities for the quarter that ended in Mar. 2026 was €1.17 Mil.

Simris Alg AB's quarterly other current liabilities declined from Sep. 2025 (€2.68 Mil) to Dec. 2025 (€2.06 Mil) and declined from Dec. 2025 (€2.06 Mil) to Mar. 2026 (€1.17 Mil).

Simris Alg AB's annual other current liabilities increased from Dec. 2023 (€1.01 Mil) to Dec. 2024 (€1.13 Mil) and increased from Dec. 2024 (€1.13 Mil) to Dec. 2025 (€2.06 Mil).

Simris Alg AB Other Current Liabilities Related Terms

Simris Alg AB Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Simris Alg AB's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simris Alg AB Other Current Liabilities Chart

Simris Alg AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.65 2.03 1.01 1.13 2.06

Simris Alg AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.88 2.08 2.68 2.06 1.17
FRA:5LU
19GF Score
Simris Alg AB FRA:5LU
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Simris Alg AB Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €1.17 Mil mean?
Simris Alg AB (FRA:5LU) has a Other Current Liabilities of €1.17 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Simris Alg AB.
Is Simris Alg AB's Other Current Liabilities too high?
Simris Alg AB's current Other Current Liabilities is €1.17 Mil. Overall, Simris Alg AB has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Simris Alg AB's Other Current Liabilities compare to VRTX and REGN?
Simris Alg AB's Other Current Liabilities of €1.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Simris Alg AB. Simris Alg AB's current Other Current Liabilities is €1.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simris Alg AB stock overvalued right now?
Simris Alg AB (FRA:5LU) has a current Other Current Liabilities of €1.17 Mil. The current Other Current Liabilities is €1.17 Mil. Simris Alg AB's overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Simris Alg AB (FRA:5LU), the current Other Current Liabilities is €1.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Simris Alg AB Business Description

Other Exchanges SIMRIS B:Sweden
Address Herrestadsvagen 24A, Hammenhog, SWE, 276 50
Simris Alg AB is a biotechnology company, engaged in research, development and production of bioactive substances from microalgae, for nutraceutical, cosmeceutical and pharmaceutical applications. The company's technology provides access to bioactive substances with novel functions, while replacing unsustainable raw materials from endangered marine species and ecosystems. Its first commercialised range is a series of omega-3 health supplements marketed under the company's own brand.
19GF Score

Get the complete analysis for FRA:5LU

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price